• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oramed inks deal to commercialize oral insulin in the Republic of Korea

November 14, 2022 By Sean Whooley

Oramed LogoOramed Pharmaceuticals (Nasdaq:ORMP) announced today that it entered into a distribution agreement for its oral insulin candidate in the Republic of Korea.

The New York-based developer of oral drug delivery platforms entered into an exclusive commercial distribution agreement with Medicox. The agreement covers the distribution of ORMD-0801 in the Republic of Korea (formerly South Korea).

Medicox, a biotech company with partnerships in Korea, received an exclusive license for the candidate. It allows the company to apply for regulatory approval and distribute the oral insulin candidate for 10 years in Korea. Medicox holds responsibility for gaining such regulatory approval in the country.

“This collaboration offers Oramed a great opportunity to participate in the large and growing Korean market and leverages the commercialization strength of our partner, while allowing Oramed to focus on other key markets, including the United States,” said Oramed CEO Nadav Kidron.

The agreement sees Medicox purchase ORMD-0801 at an agreed-upon transfer price. Additional payments to Oramed total up to $18 million in developmental milestones and up to 15% royalties on gross sales. The company received $2 million already.

Oramed currently has its ORMD-0801 candidate in two pivotal Phase 3 studies. It expects top-line results from its first Phase 3 study in January 2023. The company said ORMD-0801 could potentially become the first commercial oral insulin capsule for treating diabetes.

“We are very excited to grow and expand our pharma business by partnering with Oramed to bring a potentially breakthrough treatment to the Republic of Korea,” said Medicox CEO Dae Hwan Oh.

Filed Under: Business/Financial News, Diabetes, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS